-
PLGA Nanoparticles – Bridging the Gap from R&D to GMPWhitepaperPoly(lactic-co-glycolic acid) (PLGA) has emerged as a promising material for drug delivery and biomedical applications. Its exceptional biocompatibility, customizable degradation and release properties, and versatility have led to its approval by regulatory bodies like the FDA and EMA.
-
Nanomaterials for cancer nanomedicine: Case studiesWhitepaperCancer nanomedicine has emerged as a highly promising approach for improving the effectiveness and safety of cancer therapy. Nanoparticles have been engineered to selectively target cancer cells, overcome biological barriers, and deliver a wide range of therapeutic payloads including small molecules, nucleic acids, and proteins.
-
Infographic: Adapting Lateral Flow Assays for Nucleic Acid DetectionInfographicLateral flow assays are well-known for their ability to rapidly detect the presence or absence of proteins. Although easy to perform, its widespread adoption for other applications has been limited due to several constraints.
-
Ask the Experts: Considerations for Nanoparticle TherapeuticsWebinar
Join a panel of experts as they discuss nanoparticle technology and key considerations for nanoparticle-based drug delivery.
-
BioReady 150 nm Carboxyl Gold Nanoshells Covalent Conjugation ProtocolProtocolNanoComposix BioReady™ 150 nm Carboxyl Gold Nanoshells can be conjugated to proteins through carbodiimide activation chemistry. Covalent coupling of proteins (e.g. antibodies) to a gold nanoparticle surface yields a robust and stable gold particle conjugate. The BioReady™ 150 nm Carboxyl Gold Nanoshells are functionalized with a tightly bound monolayer containing terminal carboxylic acid functional groups which can be activated through EDC/Sulfo-NHS chemistry to generate gold nanoparticle-antibody amide bonds.